Comparison of Canagliflozin vs. Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Patients With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

Trial Profile

Comparison of Canagliflozin vs. Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Patients With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Jun 2018

At a glance

  • Drugs Canagliflozin (Primary) ; CD26 antigen inhibitors; Dapagliflozin; Empagliflozin; Glucagon-like peptide 1 agonist; Insulin; Sulfonylureas; Thiazolidinediones
  • Indications Cardiovascular disorders; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms OBSERVE-4D
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 24 Jun 2018 Results presented in a Janssen media release.
    • 24 Jun 2018 Results presented in an American Diabetes Association media release.
    • 24 Jun 2018 According to an American Diabetes Association media release, John Buse, MD, PhD, director of the Diabetes Center, director of the North Carolina Translational and Clinical Sciences Institute and executive associate dean for clinical research at the University of North Carolina School of Medicine, is the principal investigator of this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top